日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study

吉非替尼在老年EGFR突变晚期非小细胞肺癌患者中的药代动力学：一项前瞻性研究

期刊:BMC Pulmonary Medicine
影响因子:2.8
doi:10.1186/s12890-022-02249-8
Nio, Yuta; Ishida, Hiroo; Matsumoto, Natsumi; Kusumoto, Sojiro; Kubota, Yutaro; Tsunoda, Takuya; Sasaki, Yasutsuna; Fujita, Ken-Ichi
肺癌
肿瘤
肿瘤免疫
EGF
EGFR
细胞生物学
发表日期：2022
文献求助 收藏

Characteristics of miRNA-SNPs in healthy Japanese subjects and non-small cell lung cancer, colorectal cancer, and soft tissue sarcoma patients

健康日本受试者和非小细胞肺癌、结直肠癌及软组织肉瘤患者的miRNA-SNP特征

期刊:Non-coding RNA Research
影响因子:4.7
doi:10.1016/j.ncrna.2021.06.002
Katayama, Koki; Nakashima, Shimon; Ishida, Hiroo; Kubota, Yutaro; Nakano, Masataka; Fukami, Tatsuki; Sasaki, Yasutsuna; Fujita, Ken-Ichi; Nakajima, Miki
肺癌
肿瘤
肠癌
肿瘤免疫
miRNA
细胞生物学
发表日期：2021
文献求助 收藏

Does Industry-Conducted All-Case Surveillance of Newly Approved Oncology Drugs Contribute to the Revision of Package Inserts in Japan?

日本制药行业开展的针对新批准肿瘤药物的全病例监测是否有助于修订药品说明书？

期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.12644
Suzuki, Akiyuki; Sato, Hitoshi; Sasaki, Yasutsuna
肿瘤
肿瘤免疫
发表日期：2019
文献求助 收藏

Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan

日本抗癌药物成本与临床疗效之间缺乏相关性

期刊:Cancer Science
影响因子:4.3
doi:10.1111/cas.13831
Satoh, Etsuko; Sasaki, Yasutsuna; Ohkuma, Ryotaro; Takahashi, Takehiro; Kubota, Yutaro; Ishida, Hiroo; Hamada, Kazuyuki; Kiuchi, Yuji; Tsunoda, Takuya
肿瘤
肿瘤免疫
发表日期：2018
文献求助 收藏

S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study

S-1联合奥沙利铂（SOX）加贝伐单抗对比mFOLFOX6联合贝伐单抗作为转移性结直肠癌患者一线治疗方案：开放标签、非劣效性、随机III期SOFT研究的最新总生存期分析

期刊:ESMO Open
影响因子:8.3
doi:10.1136/esmoopen-2016-000135
Baba, Hideo; Yamada, Yasuhide; Takahari, Daisuke; Matsumoto, Hiroshi; Yoshida, Kazuhiro; Nakamura, Masato; Yoshida, Motoki; Iwamoto, Shigeyoshi; Shimada, Ken; Komatsu, Yoshito; Sasaki, Yasutsuna; Satoh, Taroh; Takahashi, Keiichi; Mishima, Hideyuki; Muro, Kei; Watanabe, Masahiko; Sakata, Yuh; Morita, Satoshi; Shimada, Yasuhiro; Sugihara, Kenichi
肿瘤
肠癌
肿瘤免疫
SOX
发表日期：2017
文献求助 收藏

Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation

在携带 EGFR 突变的肺腺癌中发现了独特的阿法替尼耐药机制

期刊:Molecular Cancer Research
影响因子:4.1
doi:10.1158/1541-7786.MCR-16-0482
Toshimitsu Yamaoka, Tohru Ohmori, Motoi Ohba, Satoru Arata, Yasunori Murata, Sojiro Kusumoto, Koichi Ando, Hiroo Ishida, Tsukasa Ohnishi, Yasutsuna Sasaki
肿瘤
肺癌
发表日期：2017
文献求助 收藏

Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites

转运蛋白 P-糖蛋白和乳腺癌耐药蛋白参与多激酶抑制剂瑞戈非尼及其活性代谢物的真皮分布

期刊:Journal of Pharmaceutical Sciences
影响因子:3.7
doi:10.1016/j.xphs.2017.04.064
Ken-Ichi Fujita, Yusuke Masuo, Erina Yamazaki, Toshiki Shibutani, Yutaro Kubota, Noritaka Nakamichi, Yasutsuna Sasaki, Yukio Kato
代谢
肿瘤
乳腺癌
发表日期：2017
文献求助 收藏

A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study)

一项针对具有特定 UGT1A1 基因型的复发/转移性乳腺癌患者的伊立替康联合 S-1 治疗的 I/II 期药代动力学/药效学研究（JBCRG-M01 研究）

期刊:Cancer Medicine
影响因子:3.1
doi:10.1002/cam4.1258
Ishiguro, Hiroshi; Saji, Shigehira; Nomura, Shogo; Tanaka, Sunao; Ueno, Takayuki; Onoue, Masahide; Iwata, Hiroji; Yamanaka, Takeharu; Sasaki, Yasutsuna; Toi, Masakazu
BCR
肿瘤
肿瘤免疫
乳腺癌
发表日期：2017
文献求助 收藏

Patritumab plus trastuzumab and paclitaxel in human epidermal growth factor receptor 2-overexpressing metastatic breast cancer

Patritumab 联合曲妥珠单抗和紫杉醇治疗人表皮生长因子受体 2 过表达的转移性乳腺癌

期刊:Cancer Science
影响因子:4.5
doi:10.1111/cas.13017
Hirofumi Mukai, Toshiaki Saeki, Kenjiro Aogi, Yoichi Naito, Nobuaki Matsubara, Takashi Shigekawa, Shigeto Ueda, Seiki Takashima, Fumikata Hara, Tomonari Yamashita, Shoichi Ohwada, Yasutsuna Sasaki
肿瘤
乳腺癌
Human
发表日期：2016
文献求助 收藏

Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction

吉西他滨治疗肝功能不全患者胆道癌或胰腺癌的最佳剂量

期刊:Cancer Science
影响因子:4.3
doi:10.1111/cas.12851
Shibata, Takashi; Ebata, Tomoki; Fujita, Ken-ichi; Shimokata, Tomoya; Maeda, Osamu; Mitsuma, Ayako; Sasaki, Yasutsuna; Nagino, Masato; Ando, Yuichi
胰腺癌
肿瘤
胆管癌
肿瘤免疫
发表日期：2016
文献求助 收藏